

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/516,444	02/29/2000	Patricia A. Billing-Medel	5995.US.P2	1768		
23492	7590 10/02/2003	EXAMINER				
	WEINSTOCK ABORATORIES	·	YAEN, CHRIS	YAEN, CHRISTOPHER H		
•	T PARK ROAD		ART UNIT	PAPER NUMBER		
DEPT. 377/A	AP6A	1642	1 _			
ABBOTT PA	ARK, IL 60064-6008		DATE MAILED: 10/02/2003	13		

Please find below and/or attached an Office communication concerning this application or proceeding.

	· · ·	Applicatio	n No.	Applicant(s)	<del></del>			
Office Action Summary		09/516,44	4	BILLING-MEDEL ET	BILLING-MEDEL ET AL.			
		Examiner	·	Art Unit				
•		Christophe	r H Yaen	1642				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply								
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR I MAILING DATE OF THIS COMMUNICAT nsions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communical period for reply specified above is less than thirty (30) day begind for reply is specified above, the maximum statutory are to reply within the set or extended period for reply will, be reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	FION.  CFR 1.136(a). In no every stron.  ys, a reply within the statury period will apply and will by statute, cause the appli	nt, however, may a replitory minimum of thirty (3 expire SIX (6) MONTH cation to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this comn IDONED (35 U.S.C. § 133).	nunication.			
1)⊠	Responsive to communication(s) filed o	on <u>29 February 20</u>	<u>00</u> .					
2a)□	This action is <b>FINAL</b> . 2b)	This action is i	non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
•	ion of Claims							
= -	4) Claim(s) 1-24 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.								
	6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to.							
•	Claim(s) <u>1-24</u> are subject to restriction a	nd/or election rea	irement					
•	ion Papers							
9)[	The specification is objected to by the Ex	aminer.						
10)[	The drawing(s) filed on is/are: a)[	accepted or b)	objected to by the	Examiner.				
	Applicant may not request that any objection							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
•	under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)	☐ All b)☐ Some * c)☐ None of:	umanta haya baar	rossived					
	1. Certified copies of the priority documents have been received.							
	<ul><li>2. Certified copies of the priority documents have been received in Application No</li><li>3. Copies of the certified copies of the priority documents have been received in this National Stage</li></ul>							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
	)  The translation of the foreign langua  Acknowledgment is made of a claim for de	• .						
Attachmen	t(s)							
2) 🛂 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-9 mation Disclosure Statement(s) (PTO-1449) Paper	948)		mmary (PTO-413) Paper No(s). ormal Patent Application (PTO-1				

Application/Control Number: 09/516,444

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - 1. Claims 1,2,6,8, drawn to a purified multimeric polypeptide antigen (MPA) comprising at least one BU106 polypeptide, classified in class 530, subclass 300. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)
  - II. Claims 3 and 7, drawn to a purified multimeric polypeptide antigen (MPA), comprising at least one BS106 polypeptide classified in class 530, subclass 300. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)
  - III. Claims 4,5,15,16, and 19, drawn to a method of detecting the presence of a multimeric polypeptide antigen (MPA) in a test sample, classified in class 436, subclass 500.
  - IV. Claims 9,11, 13, and 18, drawn to an antibody specific for the MPA of invention group I, classified in class 530, subclass 387.1. (Please note if this group is selected further select one sequence to be examined on the merits, and amend the claims accordingly, see below for explanation)

Application/Control Number: 09/516,444

Art Unit: 1642

- V. Claims 10 and 12, drawn to an antibody specific for the MPA of invention group II, classified in class 530, subclass 387.1.
- VI. Claim 14, drawn to a cell line, classified in class 435, subclass 325.
- VII. Claim 17, drawn to a diagnostic kit comprising breast markers, classified in class 424, subclass 184.1.
- VIII. Claims 20-24, drawn to a method of detecting cancer cells in a tissue sample from a human patient, classified in class 435, subclass 7.1.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I-II and IV-VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions differ one from the other because the products are chemically, functionally and structurally different.
- 3. Inventions III and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions differ one from the other because the methods have different purposes and functions.
- 4. Inventions IV-V, VII and III, VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Application/Control Number: 09/516,444

Art Unit: 1642

process of using that product (MPEP § 806.05(h)). In the instant case the methods can be accomplished using a materially different product, such as a peptide that is specifically labeled with a fluorochromes or with nucleic acid probes.

- 5. Inventions I-II, VI and III, VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the methods are drawn to detection while the products are drawn to the target which is being detected.
- 6. Because these inventions are distinct for the reasons given above and the search required for Group I-VIII is not required one for the other, restriction for examination purposes as indicated is proper.
- 7. Upon election of Group I, II, or IV Applicants are additionally required to elect a single Sequence identified by a specific sequence identification number, as indicated above as they apply to group(s). The recited sequences have different structures one from other and the search for the sequences would be unduly burdensome. This requirement is not to be construed as a requirement for an election of species, since each of the sequence(s) recited in alternative form is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.
- 8. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/516,444 Page 5

Art Unit: 1642

9. Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Christopher H Yaen whose telephone number is 703-

305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number

for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703-308-

0196.

Christopher Yaen Art Unit 1642 September 30, 2003 SUPERVILORY PATENT EXAMINATECHNOLOGY CENTER 1600